This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
reported.
Source of effectiveness data
The effectiveness data were derived from a single study.
Link between effectiveness and cost data
The costing was undertaken prospectively on the same patient sample as that used in the effectiveness study.
Study sample
The authors estimated that to detect a +/-15% difference in a survival rate of 50% at 20 months in the EPI-PAC group, 320 patients were needed for the study to have 80% power at the 5% significance level. Considering a 2% withdrawal rate, the total number of patients was increased to 327. The post-hoc power to detect a +/-15% difference according to the study design, based on the total events observed, was 82%.
From January 1999 to April 2002, 332 patients entered the study. Five patients were excluded from the analysis because of inadvertent randomisation (1 patient), missing medical records (2 patients) and non eligibility (2 patients, one with a performance status of 3 and the other an initial low platelet count). Of the remaining 327 patients, 163 were randomised to group A (EPI-PAC) and 164 to group B (PAC-Cp). One patient in group A and 4 patients in group B never started chemotherapy. These 5 patients were excluded only from the analysis of treatment characteristics and toxicity. The median age was 59 years in group A (range: 30 -78) and 59 years in group B (range: 27 -78).
Study design
This was a randomised controlled trial. The study appears to have been a multi-centre trial, although the authors did not report the number of centres taking part in the study. The patients were randomised centrally and stratified according to the history of previous adjuvant chemotherapy and risk category. The risk categories were based on the following criteria: free interval from initial radical surgery to first recurrence more than 5 years with only osseous or with only loco regional metastases; free interval 1 to 5 years and absence of visceral metastases; and all others. The groups were followed for a median of 23.5 months (range: 0.1 -49.5). The authors reported that 5 patients in group A and 2 patients in group B were lost to follow-up. The authors also provided the number of patients who withdrew (voluntarily or not). It was unclear whether these patients should be included in the number of patients lost to follow-up.
Analysis of effectiveness
The clinical study was conducted on an intention to treat basis. The primary health outcome was survival. The secondary outcomes included the overall (complete plus partial) response rate, the time to treatment failure (TTF), compliance with treatment and severe toxic effects. In the case of a complete response, the duration of response was calculated from the date when complete response was documented until the date of progression; in the case of a partial response, the duration was calculated from the initiation of chemotherapy until the date of progression. The TTF was calculated from a randomisation date to the date when progression of the disease was documented. Survival was calculated from the randomisation date to the date of the last contact or to the date of death. Quality of life was also assessed using the Greek version of the EORTC QLQ-C30, both at baseline and at the end of the study. Major patient and tumour characteristics were generally equally distributed in the two groups of patients. The exception was the rate of osseous metastases, which was significantly higher in group B (44% versus 57%; p=0.02).
Effectiveness results
In total, 127 patients (78%) in group A and 135 (82%) in group B completed at least 6 cycles of treatment. Overall, 137 patients (66 patients in group A and 71 in group B) received maintenance hormonal therapy after treatment completion.
Both regimens were well tolerated. In total, 39 patients (24%) in group A and 46 (29%) in group B suffered at least one severe side effect (Grade 3 or 4).
The overall response rate was 47% (95% confidence interval, CI: 38.8 -54.6) in group A and 41% (95% CI: 33.25 -48.8) in group B, (p=0.32).
The median duration of response was 8.98 months (range: 1.34 -38+) in group A and 13.8 months (range: 3.6 -41+) in group B, (p=0.01; when adjusting for maintenance hormonal treatment, p=0.006).
The median duration of complete response was 5.4 months (range: 1.34 -35.05+) in group A, whereas in group B, it had not yet been reached (range: 3.6 -27.7+ months).
The median time to achieve complete response was 4.2 months (range: 1.4 -4.85) in group A and 4 months (range: 1.9 -5.7) in group B.
The median TTF was 8.1 months (range: 0.1 -42.7+; 95% CI: 7.0 -9.2) in group A and 10.8 months (range: 0.1 -40.7+; 95% CI: 8.9 -12.6) in group B, (p = 0.04; when adjusting for maintenance hormonal treatment, p=0.02).
Median survival was 22.4 months (range: 0.1 -42.7+; 95% CI: 17.8 -27.0) in group A and 27.8 months (range: 0.26 -49.5+; 95% CI: 20.8 -34.9) in group B, (p=0.25; when adjusting for maintenance hormonal treatment, p=0.26).
Of the 322 patients, 98 (48 of group A and 50 of group B; 30%) had both baseline and end of study quality of life assessments. PAC-Cp (group B) was associated with significant improvements in the emotional functioning scale, (p=0.01) and sleep disturbance symptoms, (p=0.01) in comparison with EPI-PAC (group A). The result was non significant when using the appropriate Bonferroni adjustment.
Clinical conclusions
The study did not identify a significant difference in median survival when EPI was substituted by Cp, in combinations with PAC.
Measure of benefits used in the economic analysis
As the results of the trial indicated that there were no significant differences in median survival between the two treatment groups, a cost-minimisation analysis was carried out.
Direct costs
The direct costs included in the analysis were those of the Greek NHS. These were: chemotherapy, concomitant and other medications used in the case of adverse events; infusions in the outpatient setting; hormone therapy and consolidation radiotherapy after chemotherapy in selected cases; subsequent hospitalisations and visits to health professionals due to adverse events or follow-ups; and all laboratory imaging examinations carried out during the chemotherapy period, or for the treatment of adverse events associated with drug toxicity or patient health deterioration.
The costs and the quantities were not reported separately. The resource use data were obtained from the clinical study and were combined with unit cost data from Greek national sources and the database of the University General hospital of Patras. The time horizon of the economic analysis was the same as that used in the clinical study (approximately 2 years), hence discounting was not necessary and was not performed. The study reported the mean costs. The price year was not reported. comparable at analysis in terms of major patient and tumour characteristics, but the rate of osseous metastases was significantly higher in group B (44% versus 57%; p=0.02). The authors performed appropriate statistical analyses to detect any statistically significant differences between the two groups. However, even though the study was powered to detect a +/-15% difference in survival with 82% power, the authors acknowledged that the study was not powered to detect smaller, but meaningful differences in survival between the two groups.
Validity of estimate of measure of benefit
Validity of estimate of costs
All the categories of cost relevant to the health service perspective adopted were included in the analysis, and all relevant costs appear to have been included. Although the costs and the quantities were not reported separately, which will limit the generalisability of the authors' results, the authors did break down the mean costs per therapy group (i.e. the mean cost of chemotherapy, drugs, or hospitalisation per patient). The resource use data were derived from the clinical study, while the unit costs were derived from published sources and a University hospital. Appropriate statistical analyses, using bootstrap techniques, were undertaken to detect statistically significant differences in mean costs between the two groups. Since the costs were incurred during approximately 2 years, discounting was not relevant and was not performed. The price year was not reported, which will hamper any future inflation exercises.
